Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Pingda Ren
A Type-Ii Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of BCR-Abl
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
Related publications
Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Broad Spectrum Alkynyl Inhibitors of T315I BCR-Abl
Bioorganic and Medicinal Chemistry Letters
Organic Chemistry
Molecular Medicine
Molecular Biology
Biochemistry
Clinical Biochemistry
Pharmaceutical Science
Drug Discovery
The Gatekeeper Mutation T315I Confers Resistance Against Small Molecules by Increasing or Restoring the ABL-kinase Activity Accompanied by Aberrant Transphosphorylation of Endogenous BCR, Even in Loss-Of-Function Mutants of BCR/ABL
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
BCR-ABL Tyrosine Kinase
Science-Business eXchange
Discovery and Characterization of a Novel Potent Type II Native and Mutant BCR-ABL Inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)
Oncotarget
Oncology
Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL T315I Point Mutation
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Protein Kinase CKIIa Interacts With the BCR Moiety of BCR/Abl and Mediates Proliferation of BCR/Abl-Expressing Cells
Oncogene
Cancer Research
Genetics
Molecular Biology
Kinase Domain Mutants of BCR Enhance BCR-Abl Oncogenic Effects
Oncogene
Cancer Research
Genetics
Molecular Biology
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571
Clinical Cancer Research
Cancer Research
Oncology
